We are pleased to find our previously published results ([@B1],[@B2]) confirmed by the report of Keenan et al. ([@B3]). In their cohort of individuals with very long-standing type 1 diabetes, 67.4% of patients had residual endogenous insulin production, and in nine postmortem examinations of pancreatic tissue, insulin positive cells were found. However, we respectfully disagree that this is a surprising finding. We recently reported that many patients with long-standing type 1 diabetes maintain the capacity to secrete small amounts of insulin in a regulated manner ([@B1],[@B2]). Their residual β-cells responded to both physiological (mixed meal) and pharmacological (arginine) stimuli. We further tested the hypothesis that expanding this residual β-cell mass might be a promising approach to treatment ([@B1]). Though our experimental conditions did not result in an improvement of β-cell mass or function, we strongly believe that expansion of remaining β-cells is a promising approach for future research.

Might the C-peptide results of the Joslin Medalists have been an underestimate of their true insulin secretory capacity? We had observed that the remaining β-cells\' insulin secretion could be suppressed by exogenous insulin administration ([@B1]). Therefore, we wonder whether Keenan et al. would have found more C-peptide had the investigators tested the individuals under different conditions (some patients received insulin injections immediately before the mixed meals, which might have suppressed their C-peptide levels). The merit of the Joslin Medalist Study should, however, in no way be denigrated, especially because of its unique collection of clinical data and comparison with postmortem results.
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